Scientists have discovered new antibodies that neutralize viruses that cause dengue, potentially putting a universal vaccine within reach for a mosquito-borne illness that strikes an estimated 400 million people a year.
The antibodies are effective against all four dengue viruses, according to an article published Monday in Nature Immunology. A vaccine being developed by Sanofi has had mixed results, helping to protect people from three of the viruses in one trial, and in all four in a bigger study.
Dengue is carried by mosquitoes and is common in the tropics, with Brazil and Indonesia reporting the most cases. About a quarter of those infected develop symptoms, with most enduring pain and a fever that lasts about a week. The most severe cases develop hemorrhagic fever, which can be fatal. About 20,000 people die from dengue each year, according to the World Health Organization.
With your current subscription plan you can comment on stories. However, before writing your first comment, please create a display name in the Profile section of your subscriber account page.